Search research articles
Contact Us
Filters
Showing results (191-200 of 216) with videos related to
Page
of 22
Sort By:
BMC Cancer
|
November 22, 2025
CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancer
Alessandro Passardi, Francesco Giulio Sullo, Alessandro Bittoni, et al.
Journal of Geriatric Oncology
|
February 6, 2014
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer
Ugo De Giorgi, Karim Rihawi, Michele Aieta, et al.
Cytotherapy
|
July 24, 2024
Dendritic cell vaccines as cancer treatment: focus on 13 years of manufacturing and quality control experience in advanced therapy medicinal products
Anna Maria Granato, Elena Pancisi, Claudia Piccinini, et al.
Breast Cancer Research and Treatment
|
December 7, 2010
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer
Dino Amadori, Rosella Silvestrini, Mario De Lena, et al.
Clinical Genitourinary Cancer
|
December 28, 2013
Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis
Ugo De Giorgi, Emanuela Scarpi, Cosimo Sacco, et al.
Trials
|
August 2, 2020
PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial
Oriana Nanni, Pierluigi Viale, Bernadette Vertogen, et al.
Clinical Lung Cancer
|
December 30, 2015
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy
Paola Ulivi, Elisa Chiadini, Claudio Dazzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 19, 2026
Impact of Circulating Tumor DNA and Copy-Number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated With Salvage High-Dose Chemotherapy
Milena Urbini, Thomas F Eleveld, Maurizio Polano, et al.
International Journal of Molecular Sciences
|
March 29, 2019
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin
Serena De Matteis, Emanuela Scarpi, Anna Maria Granato, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 2, 2021
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study
Vincenza Conteduca, Daniel Wetterskog, Elena Castro, et al.
Page
of 22
Search research articles
Search
Showing results (191-200 of 216) with videos related to
Sort By:
Page
of 22
BMC Cancer
|
November 22, 2025
CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancer
Alessandro Passardi, Francesco Giulio Sullo, Alessandro Bittoni, et al.
Journal of Geriatric Oncology
|
February 6, 2014
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer
Ugo De Giorgi, Karim Rihawi, Michele Aieta, et al.
Cytotherapy
|
July 24, 2024
Dendritic cell vaccines as cancer treatment: focus on 13 years of manufacturing and quality control experience in advanced therapy medicinal products
Anna Maria Granato, Elena Pancisi, Claudia Piccinini, et al.
Breast Cancer Research and Treatment
|
December 7, 2010
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer
Dino Amadori, Rosella Silvestrini, Mario De Lena, et al.
Clinical Genitourinary Cancer
|
December 28, 2013
Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis
Ugo De Giorgi, Emanuela Scarpi, Cosimo Sacco, et al.
Trials
|
August 2, 2020
PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial
Oriana Nanni, Pierluigi Viale, Bernadette Vertogen, et al.
Clinical Lung Cancer
|
December 30, 2015
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy
Paola Ulivi, Elisa Chiadini, Claudio Dazzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 19, 2026
Impact of Circulating Tumor DNA and Copy-Number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated With Salvage High-Dose Chemotherapy
Milena Urbini, Thomas F Eleveld, Maurizio Polano, et al.
International Journal of Molecular Sciences
|
March 29, 2019
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin
Serena De Matteis, Emanuela Scarpi, Anna Maria Granato, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 2, 2021
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study
Vincenza Conteduca, Daniel Wetterskog, Elena Castro, et al.
Page
of 22